MedStar Health, Columbia, MD 21044, USA.
Georgetown University Medical Center, Washington, DC 20057, USA.
Pharmacogenomics. 2020 Oct;21(15):1085-1094. doi: 10.2217/pgs-2020-0064. Epub 2020 Sep 24.
Identify the attitudes and interests of primary care providers (PCPs) in applying clinical pharmacogenomics (PGx) test results. A questionnaire was designed and then disseminated to PCPs across the MedStar Health System. Ninety of 312 (29%) PCPs responded and were included in analyses. Seventy-six (84%) had heard of PGx and 12 (13%) previously ordered PGx testing. Most, 68 (76%), believed PGx can improve care; however, a minority, 23 (26%), reported confidence in using PGx in prescribing decisions. Sixty-four (70%) wanted a pharmacist consultation. PCPs desired PGx for antidepressants (75%), proton pump inhibitors (72%) and other medications. Most PCPs felt unprepared to interpret PGx results and desired pharmacist consultations. These data can inform future PGx implementations with PCPs.
确定初级保健提供者（PCP）在应用临床药物基因组学（PGx）测试结果方面的态度和兴趣。设计了一份问卷，然后分发给 MedStar 健康系统的 PCP。312 名 PCP 中有 90 名（29%）做出了回应并被纳入分析。76 名（84%）听说过 PGx，12 名（13%）之前曾订购过 PGx 检测。大多数人（68%）认为 PGx 可以改善治疗；然而，少数人（26%）表示在开具处方决策时对使用 PGx 有信心。64 名（70%）希望与药剂师咨询。PCP 希望将 PGx 用于抗抑郁药（75%）、质子泵抑制剂（72%）和其他药物。大多数 PCP 觉得准备不足，无法解释 PGx 结果，并希望与药剂师咨询。这些数据可以为未来与 PCP 一起实施 PGx 提供信息。
